SEC 8-K and 6-K filings classified by Claude with reasoning, plus Form 4 insider transactions. Ingested from EDGAR’s filing stream in near-real time, reconciled overnight.
Showing material events only. Routine administrative filings — bylaw amendments, technical fund updates, procedural FD disclosures — are filtered out so the front page stays signal-dense.
Andrew Safran was appointed to the Board of Directors of Ferrellgas, Inc. on May 21, 2026, bringing significant energy and investment banking experience. Pamela A. Breuckmann was appointed to Vice Chair of the Board. These board appointments and promotion represent material governance changes affecting the company's strategic direction.
View raw filing on EDGAR →Medalist's subsidiary OWN has entered into a $15.8 million Pledged Asset Line (PAL) Agreement with Charles Schwab, a material financing arrangement secured by a brokerage account. While this is a credit facility disclosure rather than a covenant breach or going-concern issue, the establishment of a significant margin credit facility with customary default triggers (including bankruptcy initiation and collateral insufficiency) is material to investors assessing the company's liquidity and financial obligations, but does not fit neatly into the more specific event categories.
View raw filing on EDGAR →The filing discloses two distinct events: (1) a segment reorganization moving a titanium alloy location from Engine Products to Engineered Structures, which the company explicitly states had "no impact on the Company's consolidated results, financial position or cash flows" and is not a restatement; and (2) a material debt refinancing transaction on May 22, 2026, involving early prepayment of ¥29,702 million in JPY Term Loan debt and entry into a cross-currency swap on $300 million of 6.750% Notes due 2028, expected to reduce annual interest expense by approximately $12 million. The segment reorganization is administrative and immaterial, but the debt refinancing is a material financial transaction affecting the company's capital structure and interest expense. This combination does not fit cleanly into a single taxonomy category (not a restatement, not a covenant breach, not M&A), making "other_material" the most appropriate classification.
View raw filing on EDGAR →The filing discloses the appointment of Jason B. Rush as Chairman of the Board on May 27, 2026, following his election to the Board at the May 7, 2026 annual meeting. While Rush was already serving as President and CEO (appointed January 1, 2026), the principal disclosed action here is his elevation to Chairman, a material executive appointment. The extensive employment history and compensation reference underscore the significance of this role change.
View raw filing on EDGAR →The Board approved a $40 million share repurchase program on May 28, 2026, which is a material capital allocation decision that would affect investor assessment of the company's financial strategy and use of cash. While share repurchases are common corporate actions, a $40 million authorization represents a significant commitment of capital and signals management's confidence in valuation. This does not fit neatly into the more specific event categories (it is not an earnings release, executive change, M&A activity, or financial restatement), making "other_material" the most appropriate classification.
View raw filing on EDGAR →This is a clear disclosure of shareholder vote results from Merck's Annual Meeting of Shareholders held on May 26, 2026, filed under Item 5.07. The filing reports voting outcomes on six matters: election of 13 directors, advisory vote on named executive officer compensation, ratification of the independent auditor, and three shareholder proposals. All proposals passed with majority support, and the detailed vote tallies (votes for, against, abstentions, and broker non-votes) are provided for each matter, which is material to investors' understanding of shareholder governance and company direction.
View raw filing on EDGAR →Hudson Technologies received a bridge modification from the Defense Logistics Agency extending an existing contract expiration from July 29, 2026 to November 29, 2026, with two additional three-month renewal options. While this is a material contract extension for a significant government customer (DLA), it does not fit neatly into the more specific event categories (not M&A, not an impairment, not a covenant breach). The extension of a major defense contract is material to investor assessment of the company's revenue continuity and operational stability, warranting disclosure as an other_material event.
View raw filing on EDGAR →ClearSign suspended and terminated its ATM (At The Market) prospectus supplement on May 26, 2026, halting the ability to sell up to $10.39 million in common stock under the ATM Agreement. While this is a material event affecting the company's capital-raising capacity, it does not fit cleanly into the dilutive_issuance category (which applies to actual unregistered sales) nor any other specific taxonomy event. The suspension of an active equity offering program is material to investors assessing the company's liquidity and financing flexibility, warranting disclosure as other_material.
View raw filing on EDGAR →Kathleen Shea Ballay, the Company's General Counsel and Chief Legal Officer, has announced her resignation effective July 3, 2026. This is a clear departure of a named executive officer responsible for legal affairs, a material position at any public company. The departure of a General Counsel and Chief Legal Officer is material to investors as it affects governance and legal oversight.
View raw filing on EDGAR →Aflac issued approximately ¥65.9 billion in registered senior notes across four tranches (2029, 2031, 2033, and 2036) on May 28, 2026, pursuant to a public offering under Form S-3ASR. While this is a material debt issuance that would affect a reasonable investor's assessment of the company's capital structure and financial position, it does not fit cleanly into the more specific event categories. This is a registered debt offering (not an unregistered equity issuance triggering dilutive_issuance), not a covenant breach, and not an M&A activity. The disclosure is material but best classified as other_material given the taxonomy's focus on equity issuances and specific debt-related events like covenant breaches.
View raw filing on EDGAR →First National Funding LLC entered into material definitive agreements on May 28, 2026, including a Series 2026-1 Indenture Supplement with First National Master Note Trust and U.S. Bank Trust Company, and a Risk Retention Agreement with First National Bank of Omaha, establishing a securitization structure for asset-backed financing.
View raw filing on EDGAR →First National Master Note Trust issued $500 million in publicly offered Class A Asset Backed Notes on May 28, 2026, along with $67.3 million and $73.7 million in Class B and C notes sold to an affiliate, with net proceeds of $497.5 million used to purchase credit card receivables.
View raw filing on EDGAR →The filing discloses a registered direct offering of 8,539,709 shares of common stock at $0.5855 per share, generating approximately $5.0 million in gross proceeds. Additionally, the Company amended outstanding warrants to reduce the exercise price from a weighted average of $1.78 to $0.5855 per share, affecting 15,488,570 shares. This is a material dilutive equity issuance that would significantly affect shareholder ownership and is disclosed under Item 8.01 as a registered direct offering.
View raw filing on EDGAR →Target Hospitality entered into an underwriting agreement on May 28, 2026 for a registered public offering of 7,000,000 shares of common stock at $17.00 per share, with an additional 30-day option for 1,050,000 shares. Although the Company itself receives no proceeds (the selling stockholders are TDR Capital-controlled entities), this is a material dilutive equity issuance that increases shares outstanding and affects existing shareholders' ownership percentages. The disclosure of a registered public offering of this magnitude is material to investors.
View raw filing on EDGAR →The filing discloses an increase to the maximum aggregate offering amount under an At Market Issuance Sales Agreement (ATM offering) by $2,956,000 in common stock. This is a dilutive equity issuance that expands the company's ability to raise capital through unregistered or registered equity sales, which materially affects shareholder dilution and the company's capital structure. The company has already sold approximately $3,445,000 under the prior supplement, indicating active use of this facility.
View raw filing on EDGAR →The filing explicitly discloses that Photronics issued a press release on May 28, 2026 reporting second quarter fiscal 2026 financial results, with the press release furnished as Exhibit 99.1. This is a standard earnings release disclosure under Item 2.02, which would materially affect a reasonable investor's assessment of the company's financial performance.
View raw filing on EDGAR →Ionis disclosed positive Phase 3 pivotal trial results for bepirovirsen, a partnered investigational drug for chronic hepatitis B licensed to GSK, demonstrating a 19% functional cure rate and meeting primary endpoints with clinical efficacy superior to standard of care. This material clinical milestone affects investor assessment of the company's pipeline prospects and partnership value.
View raw filing on EDGAR →This is a Form 8-K Item 5.07 disclosure of shareholder meeting results. Although Proposal 1 was not ultimately submitted to a vote due to lack of quorum, the filing reports on the reconvened special meeting held on May 21, 2026, and discloses voting results for the Series I preferred stockholder and common stockholders on Proposal 1 (which sought to eliminate a supermajority voting requirement). The disclosure of shareholder voting activity and meeting outcomes is the core purpose of Item 5.07, making this a shareholder_vote_results event. The failure to achieve quorum and the resulting non-submission of the proposal is material information affecting the company's governance structure.
View raw filing on EDGAR →ePlus Inc. announced financial results for its fourth quarter and fiscal year ended March 31, 2026, via press release attached as Exhibit 99.1, including reconciliation of GAAP and non-GAAP measures.
View raw filing on EDGAR →The filing discloses termination of the 2027 Notes ($400 million principal) through redemption using proceeds from a new $400 million 2031 Notes issuance. While this involves debt refinancing, it does not fit cleanly into the standard taxonomy: it is neither a covenant breach (no default triggered), nor a material impairment, nor a dilutive equity issuance. The event is material to investors as it affects the company's capital structure and debt maturity profile, but the specific mechanics—a routine debt refinancing—lack the acute financial distress signals of other categories.
View raw filing on EDGAR →The Fund reported its NAV per share of $26.10 as of April 30, 2026, aggregate NAV of $1,625.2 million, and key leverage metrics including a debt-to-equity ratio of 0.91x, along with progress on its continuous $2.5 billion public offering. This disclosure is material to investors assessing the fund's capital structure and growth trajectory.
View raw filing on EDGAR →The filing discloses the appointment of Matt McLaughlin as Chief Executive Officer of comScore, Inc., announced via press release on May 28, 2026. The appointment of a CEO is a material executive change that would affect a reasonable investor's assessment of the company's leadership and direction. Although disclosed under Item 7.01 (Regulation FD Disclosure) rather than the typical Item 5.02, the substance is clearly an executive appointment.
View raw filing on EDGAR →Sono-Tek Corporation disclosed financial results for the fiscal year ended February 28, 2026, via a press release issued on May 28, 2026 and furnished under Regulation FD.
View raw filing on EDGAR →Gideon Yu, a Board member since 2021 and member of the Nominating and Corporate Governance Committee and Risk, Compliance and Planning Committees, resigned effective immediately on May 22, 2026.
View raw filing on EDGAR →Hanmi Financial held its Annual Meeting of Stockholders on May 27, 2026, with voting results disclosed on four matters: election of ten board directors, advisory vote on executive compensation, approval of the 2026 Employee Stock Purchase Plan, and ratification of Crowe LLP as independent auditor.
View raw filing on EDGAR →Hadron Energy Operating Company completed a material business combination with GigCapital7 Corp on May 22, 2026, resulting in a change of control, company rename to Hadron Energy, Inc., and new Nasdaq ticker symbols (HDRN/HDRNW). The filing also discloses entry into ancillary definitive agreements (Registration Rights Agreement and Lock-Up Agreement) in connection with the closing of the business combination.
View raw filing on EDGAR →This disclosure reports Amendment No. 1 to a material merger agreement between Axalta and AkzoNobel, originally entered into on November 18, 2025. The amendment modifies the merger structure by introducing a second wholly owned subsidiary and a second merger step to optimize tax integration, but does not change the fundamental tax consequences for Axalta shareholders. The amendment is material M&A activity under Item 1.01, as it modifies a previously disclosed material definitive agreement governing a change of control transaction.
View raw filing on EDGAR →This Item 5.07 discloses the results of Yum China's 2026 annual meeting of stockholders held on May 28, 2026, including voting outcomes for five proposals: election of 12 directors, ratification of auditors (KPMG Huazhen LLP and KPMG), advisory approval of named executive officer compensation, authorization for share issuances up to 20%, and authorization for share repurchases up to 10%. The detailed voting tallies (For/Against/Abstain/Broker Non-Votes) for each proposal are the core disclosure required by Item 5.07.
View raw filing on EDGAR →Burlington Stores issued a press release on May 28, 2026 announcing operating results for the first quarter ended May 2, 2026, filed under Item 2.02 (Results of Operations and Financial Condition). This is a standard quarterly earnings disclosure, which is material to investors assessing the company's financial performance and operational trends.
View raw filing on EDGAR →Peabody Energy announced a private offering of $225 million in Convertible Senior Notes due 2031 to qualified institutional buyers under Rule 144A. Convertible notes are inherently dilutive securities that can be converted into equity, and a $225 million offering represents a material capital raise that would affect investor assessment of the company's capital structure and shareholder dilution risk.
View raw filing on EDGAR →Kohl's Corporation issued a press release reporting earnings for the quarter ended May 2, 2026, with presentation materials for a quarterly earnings conference call. The disclosure includes updated fiscal guidance and is furnished under Regulation FD.
View raw filing on EDGAR →Tim McHugh was elected to the Board of Directors of FrontView REIT, Inc., effective May 28, 2026. McHugh brings substantial experience as Co-President and CFO of Welltower Inc., a public REIT, and qualifies as independent under NYSE listing standards.
View raw filing on EDGAR →Caesars Entertainment entered into a definitive merger agreement on May 27, 2026, whereby a subsidiary of Fertitta Gaming Holdco will merge with Caesars, with Caesars continuing as a wholly owned subsidiary. The merger consideration is $31.00 per share in cash (plus a ticking fee if closing is delayed), subject to stockholder approval and gaming regulatory approvals.
View raw filing on EDGAR →Aveanna Healthcare entered into the thirteenth amendment to its First Lien Credit Agreement on May 26, 2026, resulting in a repricing of facilities with a 0.50% reduction to applicable interest rate margins and refinancing of $1.318 billion in term loans and a $250 million revolving credit facility. While this is a material debt refinancing that affects the company's capital structure and cost of borrowing, it does not fit neatly into the more specific event categories (not a covenant breach, not a going-concern disclosure, not a material impairment). The repricing and refinancing would be material to investors assessing the company's financial obligations and leverage position.
View raw filing on EDGAR →The filing discloses a material regulatory milestone: on May 27, 2026, the FDA released MannKind from a five-year postmarketing requirement to conduct a large randomized controlled trial (8,000-10,000 patients) assessing pulmonary malignancy risk with Afrezza. This removal of a significant regulatory burden is favorable to the company and would affect a reasonable investor's assessment of Afrezza's regulatory pathway and commercial prospects. The disclosure also updates clinical trial progress (INHALE-1st enrollment expansion) and a pending pediatric BLA with a May 29, 2026 PDUFA date. While this is primarily a positive regulatory/clinical update rather than a discrete event type (not a restatement, impairment, covenant breach, or other specific category), the material nature of the FDA's release from the postmarketing requirement warrants classification as a material event.
View raw filing on EDGAR →Seagate completed a privately negotiated exchange of $185.9 million in convertible notes for cash and 2,023,124 ordinary shares, a material dilutive equity issuance that reduces debt while increasing share count and affecting the company's capital structure.
View raw filing on EDGAR →MasterBrand completed its merger with American Woodmark on May 28, 2026, funded by a $375 million Term Loan A drawdown to repay existing indebtedness of approximately $367.5 million. The transaction represents a material acquisition that significantly affects the registrant's capital structure, asset base, and strategic direction.
View raw filing on EDGAR →Three former American Woodmark directors—Andrew Cogan, Philip Fracassa, and Daniel Hendrix—were appointed as independent directors to MasterBrand's Board effective at the merger closing, expanding the Board from 8 to 11 directors as part of post-acquisition governance integration.
View raw filing on EDGAR →American Woodmark completed a merger with MasterBrand, becoming a wholly owned subsidiary. The transaction involved termination of the company's prior credit agreement and resulted in a change of control and material acquisition event.
View raw filing on EDGAR →American Woodmark notified Nasdaq of the merger closing and requested suspension of trading and withdrawal of its common stock from Nasdaq listing, effective May 29, 2026, with plans to file Form 25 for delisting and Form 15 for deregistration.
View raw filing on EDGAR →All board members and officers of American Woodmark ceased service effective at the closing of the merger with MasterBrand, representing a wholesale departure of the entire executive and board structure.
View raw filing on EDGAR →American Woodmark's Articles of Incorporation and Bylaws were amended and restated in connection with the merger closing, reflecting governance restructuring as part of the change of control transaction.
View raw filing on EDGAR →Material modifications to security holder rights were disclosed by reference to the Introductory Note and Item 3.01; the specific nature of the modifications cannot be determined from the Item 3.03 classification alone.
View raw filing on EDGAR →This Item 2.03 disclosure reports the creation of direct financial obligations through the issuance of consolidated obligations (bonds and discount notes) by the Federal Home Loan Bank of Pittsburgh. While the filing explicitly states "consolidated obligations issuance is material to the FHLBank," the disclosure is primarily informational and regulatory in nature—it describes the mechanism and structure of debt issuance rather than a specific material event (e.g., a covenant breach, default, or extraordinary financing arrangement). The filing does not indicate a material change in financial condition or a triggering event that would fit more specific categories like covenant_breach or dilutive_issuance.
View raw filing on EDGAR →This is a classic Item 5.07 disclosure reporting the results of CF Bankshares' Annual Meeting of Stockholders held on May 27, 2026. The filing presents voting results for three matters: election of directors (Robert E. Hoeweler and Bradley J. Ringwald), approval of a non-binding advisory resolution on named executive officer compensation (Proposal 2), and ratification of Plante & Moran PLCC as independent auditor (Proposal 3). All proposals passed with clear majorities. Shareholder vote results are material to investors as they reflect governance outcomes and stakeholder approval of key corporate matters.
View raw filing on EDGAR →This Item 5.07 filing discloses the final voting results from Montauk Renewables' 2026 Annual Meeting of Stockholders held on May 26, 2026, including the election of two directors (Jennifer Cunningham and Sean McClain) and ratification of Grant Thornton LLP as independent auditor. The disclosure of shareholder vote outcomes is a core Item 5.07 event and is material to investors as it confirms board composition and auditor appointment.
View raw filing on EDGAR →Fidelity Private Credit Fund disclosed results of operations and financial condition as of April 30, 2026, incorporating supplementary financial disclosures and earnings-related announcements under Regulation FD.
View raw filing on EDGAR →CVC-PE Global Private Equity Fund disclosed an unregistered sale of limited partnership units totaling approximately $31.9 million across three classes (R-S, R-I, and C Units) on May 1, 2026, as part of its continuous private offering, exempt from Securities Act registration under Section 4(a)(2) and Regulation D.
View raw filing on EDGAR →The filing discloses a press release issued on May 27, 2026 announcing financial results for the quarter ended March 31, 2026, with the press release furnished as Exhibit 99.1. This is a standard quarterly earnings release disclosure under Item 2.02, which is material to investors as it provides periodic financial performance information.
View raw filing on EDGAR →Royalty Pharma entered into a material definitive agreement for a $1.8 billion unsecured revolving credit facility that refinances and replaces an existing credit agreement, with a 5-year maturity and customary financial covenants, representing a significant capital structure change affecting the company's liquidity and financial flexibility.
View raw filing on EDGAR →